Biogen (NASDAQ: BIIB) and Auxilium Pharmaceuticals (NASDAQ:AUXL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitabiliy, analyst recommendations, earnings and institutional ownership.
Institutional & Insider Ownership
88.8% of Biogen shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Biogen and Auxilium Pharmaceuticals net margins, return on equity and return on assets.
This is a breakdown of current ratings and recommmendations for Biogen and Auxilium Pharmaceuticals, as reported by MarketBeat.com.
Biogen currently has a consensus price target of $331.23, indicating a potential upside of 15.23%. Given Biogens higher possible upside, equities research analysts plainly believe Biogen is more favorable than Auxilium Pharmaceuticals.
Valuation & Earnings
This table compares Biogen and Auxilium Pharmaceuticals gross revenue, earnings per share (EPS) and valuation.
Biogen has higher revenue and earnings than Auxilium Pharmaceuticals.
Biogen beats Auxilium Pharmaceuticals on 9 of the 9 factors compared between the two stocks.
Biogen Company Profile
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Companys product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
Auxilium Pharmaceuticals Company Profile
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in mens healthcare. The companys products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.
Originally posted here:
Biogen (BIIB) and Auxilium Pharmaceuticals (AUXL) Head to Head Comparison - TheOlympiaReport